Regenxbio Inc (RGNX): Congress and insider trades

Who in Congress and inside the company traded RGNX, when each filing appeared, and what buying after each one would have earned against the S&P 500.

Key Facts

  • Regenxbio Inc (RGNX) is a listed stock on NASDAQ.
  • Insiders filed 2 open market buys worth $949K and 3 sells worth $718K, the latest filed 2026-08-27 (27 August 2026).
  • Data as of 2026-09-29 (29 September 2026).
Congress buys 0 0 members
Congress sells 0
Insider buys 2 $949K
Insider sells 3 $718K
Congress buys vs S&P, 90d n/a 0 scored buys
Insider buys vs S&P, 90d n/a 0 scored buys

Insider trades in RGNX

as of 2026-08-27
Open market insider trades in RGNX, newest first.
FiledInsiderTypeSharesPriceValue90 day vs S&P
27 Aug 2026 Ciongoli Gregory Austin buy 53,407 $9.36 $500K n/a
27 Aug 2026 Ciongoli Gregory Austin buy 49,196 $9.14 $450K n/a
6 Jul 2026 PAKOLA STEVE sell 2,161 $13.64 $29.5K n/a
1 Jul 2026 PAKOLA STEVE sell 36,725 $12.86 $472K n/a
1 Jul 2026 PAKOLA STEVE sell 19,608 $11.04 $216K n/a

Frequently asked questions

Who has bought RGNX?

0 Congress buys by 0 members and 2 insider buys are on file. The tables on this page list every one.

Did buying RGNX after a disclosure beat the market?

No disclosed buy of this stock has matured 90 days yet. A single stock is a small sample.

Sources: Congressional trades: STOCK Act disclosures, collected from CapitolTrades. Insider trades: SEC Form 4 filings, collected from Finviz. Prices: Yahoo Finance daily adjusted closes. Data as of 2026-09-29 (29 September 2026). About these sources.

Not investment advice. Past disclosed trades do not predict future returns. Disclosures are published late, so the trades shown are ones you could only have copied after the fact. Talk to a licensed adviser before you invest.